NOVABIO Research Profile

What Is Semaglutide (Sema)?

Semaglutide (Sema) is a peptide research entry commonly associated with GLP-1 receptor signaling literature. This page identifies the material as Semaglutide (Sema), with amino acid count 31; synonyms Semaglutide. The Semaglutide (Sema) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Approved drug products existLast verified 2026-10-06
Catalogue identitySemaglutide (Sema)
Available specifications10mg, 15mg, 20mg, 30mg, 40mg
Evidence snapshot806 trials · 5798 publications
Last verified2026-10-06

What Is Semaglutide (Sema)?

Semaglutide (Sema) is a peptide research entry commonly associated with GLP-1 receptor signaling literature. This page identifies the material as Semaglutide (Sema), with amino acid count 31; synonyms Semaglutide. The Semaglutide (Sema) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

806ClinicalTrials.gov query records
5798PubMed query records
6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Semaglutide (Sema) is organized around GLP-1 receptor research, peptide ligand profiling, signal-response analysis, and analytical peptide characterization. For Semaglutide (Sema), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / StudyPhaseStatusContextLast registry update
NCT02016911Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic ImpairmentPhase 1CompletedDiabetes, Diabetes Mellitus, Type 2, Healthy2018-05-15
NCT06292065Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide TherapyNACompletedGastroparesis2025-09-03
NCT06803888Bariatric Surgery vs. Semaglutide vs. TirzepatidePhase 4Active Not RecruitingObesity and Obesity-related Medical Conditions2026-09-03
NCT07017270Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance DialysisPhase 4RecruitingKidney Disease, Chronic, Diabetes, Dialysis, End Stage Kidney Disease (ESRD)2026-06-26
NCT07727473Preoperative Semaglutide Prior to Radical ProstatectomyEARLY_Phase 1Not Yet RecruitingProstate Cancer2026-07-27
NCT07701005Non-Invasive Hepatic and Metabolic Index Changes After Incretin Therapy in Overweight/ObesityNot statedCompletedSteatosis of Liver, Metabolic Liver Injury, Obesity, Overweight, Insulin Resistance2026-07-15

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.

Diabetes & metabolic syndrome · 2022 Jun

PMID 35623229
Selected PubMed record

Safety of Semaglutide.

Frontiers in endocrinology · 2021

PMID 34305810
Selected PubMed record

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.

Journal of the ASEAN Federation of Endocrine Societies · 2022

PMID 36578889
Selected PubMed record

Clinical Pharmacokinetics of Semaglutide: A Systematic Review.

Drug design, development and therapy · 2024

PMID 38952487
Selected PubMed record

Wegovy (semaglutide): a new weight loss drug for chronic weight management.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2022 Jan

PMID 34706925
Selected PubMed record

The Discovery and Development of Liraglutide and Semaglutide.

Frontiers in endocrinology · 2019

PMID 31031702

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend
Semaglutide (Sema)
Available Specifications
10mg, 15mg, 20mg, 30mg, 40mg
Pack Format
10 Vials
CAS Number
910463-68-2
Molecular Formula
C187H291N45O59
Molecular Weight
4113.58 g/mol
Amino Acid Count
31
Sequence
31-residue GLP-1 analogue with Aib8 and Lys26 using GLP-1(7–37) numbering; Lys26 carries the lipid-linker modification.
Synonyms
Semaglutide
Physical Form
Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 56843331 · Product form must still be matched to the catalogue and batch record.

Research Tools for Semaglutide (Sema)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA
Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA-approved semaglutide drug products exist for specific indications; NOVABIO catalogue material is not an FDA-approved drug.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Semaglutide (Sema) Research Summary

Identity

Semaglutide (Sema); specifications: 10mg, 15mg, 20mg, 30mg, 40mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

The research record for Semaglutide (Sema) is organized around GLP-1 receptor research, peptide ligand profiling, signal-response analysis, and analytical peptide characterization. For Semaglutide (Sema), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Evidence

806 registry records and 5798 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA-approved semaglutide drug products exist for specific indications; NOVABIO catalogue material is not an FDA-approved drug.

Semaglutide (Sema) is represented here by the catalogue identity Semaglutide (Sema). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg, 15mg, 20mg, 30mg, 40mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Semaglutide (Sema) is organized around GLP-1 receptor research, peptide ligand profiling, signal-response analysis, and analytical peptide characterization. For Semaglutide (Sema), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 806 ClinicalTrials.gov records and 5798 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA-approved semaglutide drug products exist for specific indications; NOVABIO catalogue material is not an FDA-approved drug. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Semaglutide (Sema) FAQ

What is Semaglutide (Sema)?

Semaglutide (Sema) is a peptide research entry commonly associated with GLP-1 receptor signaling literature. This page identifies the material as Semaglutide (Sema), with amino acid count 31; synonyms Semaglutide. The Semaglutide (Sema) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

What research records are indexed for Semaglutide (Sema)?

The synchronized query returned 806 ClinicalTrials.gov records and 5798 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Semaglutide (Sema) FDA approved?

FDA-approved semaglutide drug products exist for specific indications; NOVABIO catalogue material is not an FDA-approved drug.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources
ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved
2026-10-06T12:08:49Z
Inclusion
Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations
Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by
NOVABIO Research
Reviewed date
2026-10-06
Editorial methodology
How NOVABIO builds Research Profiles
Corrections contact
Contact NOVABIO with the page URL and source record.